A Test in Focus

Wei Shen, Ph.D., explains Mayo Clinic Laboratories' new expert-backed, hereditary oncology panels, which use next-generation sequencing to identify genetic mutations linked to increased cancer risk. By only including clinically significant genes, the panels provide clarity on diagnosis, prognosis, and treatment approaches.

By Samantha Rossi • November 16, 2021

Audrey Schuetz, M.D., discusses Mayo Clinic Laboratories' PCR assay that identifies two recently described staphylococcus species. The assay is unique in its ability to distinguish the new organisms from Staphylococcus aureus, providing clearer results that ultimately improve patient care.

By Samantha Rossi • November 9, 2021

John Mills, Ph.D., explains Mayo Clinic Laboratories' new neurofascin 155 (NF155) IgG4 antibody test, which is the first commercially available test in the U.S. to use flow cytometry to detect for NF155 antibodies and confirm diagnosis of CIDP.

By Samantha Rossi • October 5, 2021

Linda Hasadsri, M.D., Ph.D., explains how Mayo Clinic Laboratories’ inclusive approach to mitochondrial disease testing expedites diagnosis. Using innovative methodologies like custom reagents and droplet digital PCR enables precision insights on prognosis and treatment options.

By Samantha Rossi • September 28, 2021

Andrew Feldman, M.D., discusses the different tools and techniques Mayo Clinic Laboratories uses to accurately diagnose and classify T-cell lymphomas to help provide clinicians with the diagnostic answers they need to treat their patients.

By Samantha Rossi • September 21, 2021

Ann Moyer, M.D., Ph.D., explains Mayo Clinic Labs’ new focused pharmacogenomics panel, a real-time, PCR-based testing approach that assesses 10 genes known for their drug-gene associations, to provide guidance on medication selection for patients across a variety of specialities.

By Samantha Rossi • September 14, 2021

John Mills, Ph.D., explains Mayo Clinic Laboratories’ approach to MAG antibody testing. The ELISA-based assay uses higher reference ranges and human MAG antigen to detect MAG antibodies, which are associated with a rare, hard-to-treat condition known as DADS neuropathy.

By Samantha Rossi • July 27, 2021

Pua Hopson, D.O., discusses Mayo Clinic Labs’ new disaccharidase activity panel, which measures levels of five digestive enzymes to identify deficiencies that cause carbohydrate maldigestion and can lead to chronic conditions like celiac disease or inflammatory bowel disease. Performed on tissue sample biopsies during upper endoscopy, the activity panel is the gold standard test for detecting disaccharidase deficiencies.

By Samantha Rossi • June 29, 2021

Divyanshu (Div) Dubey, M.B.B.S., explains how Mayo Clinic Labs’ new Kelch-11 antibody test — the first in the world — can confirm diagnosis, guide treatment, and improve outcomes in patients affected by testicular cancer-associated paraneoplastic encephalitis.

By Samantha Rossi • June 22, 2021

Sanjeev Sethi, M.D., Ph.D., discusses how Mayo Clinic Laboratories’ new immunohistochemistry test for the detection of NELL-1 antigen, a biomarker for membranous nephropathy found in 10% to 15% of patients, provides diagnostic certainty and insight on disease expression.

By Samantha Rossi • June 15, 2021

Bobbi Pritt, M.D., discusses how Mayo Clinic Labs’ updated PCR assay for West Nile virus provides increased sensitivity to detect virus RNA in multiple sources, identifies two virus lineages, and confirms diagnosis.

By Samantha Rossi • June 8, 2021

Kevin Halling, M.D., Ph.D., explains how the MayoComplete Solid Tumor panel uses next-generation sequencing to assess 514 clinically significant, cancer-related genes for genetic alterations that offer insight on treatment effectivity.

By Samantha Rossi • June 1, 2021

Meera Sridharan, M.D., Ph.D., explains Mayo Clinic Labs’ testing approach for atypical hemolytic uremic syndrome (aHUS). The serological complement panel examines nine analytes to gain a thorough understanding of the complement cascade to confirm diagnosis and direct care.

By Samantha Rossi • May 18, 2021